NYSE:ALife Sciences
Assessing Agilent Technologies (A) Valuation As Earnings Approach And New FDA Diagnostic Approval Draws Interest
Investor focus on Agilent Technologies (A) is picking up as the life sciences tools company heads into its upcoming earnings report, with attention also on fresh FDA approval for its PD-L1 IHC 22C3 pharmDx companion diagnostic.
See our latest analysis for Agilent Technologies.
At a share price of $124.20, Agilent’s recent 1 day share price gain contrasts with a 30 day share price return of 8.03% decline and a 1 year total shareholder return of 7.45% decline. This suggests momentum has...